Polypharmacy Among Headache Patients: A Cross-Sectional Study by Ferrari, Anna et al.
ORIGINAL RESEARCH ARTICLE
Polypharmacy Among Headache Patients: A Cross-Sectional
Study
Anna Ferrari1 • Carlo Baraldi2 • Manuela Licata3 • Cecilia Rustichelli4
Published online: 11 May 2018
 The Author(s) 2018
Abstract
Background Polypharmacy can appropriately treat multi-
ple chronic conditions, but it can also increase potential
harm. Polypharmacy information for primary headaches is
minimal, despite drugs being the main tools to manage
headaches.
Objective The aim was to evaluate the prevalence, char-
acteristics and risk factors of polypharmacy in patients with
primary headaches and examine whether these variables
differ between episodic and chronic headache patients.
Methods We analysed polypharmacy (simultaneous use of
five or more medications), medication type, comorbidity,
and risk factors in 300 patients (mean age
42.81 ± 13.21 years) with primary headaches, divided into
episodic and chronic, afferent to a headache centre.
Results Patients took an average of 4.37 medications.
Polypharmacy was common in 40.7% of patients, and
among chronic patients, it reached 58.8%. Most patients
used medications (mainly nonsteroidal anti-inflammatory
drugs; 73.5%) to treat acute headaches, and 30.4% of
episodic and 64.7% of chronic sufferers underwent pro-
phylactic treatment (P\ 0.0001), mostly using antide-
pressants (77.3%). Up to 76.7% of the cohort was taking
other medications, primarily for acid-related disorders
(21.7%). Comorbidities were present in 59.7% of the
cohort. Variables significantly associated with polyphar-
macy were comorbidities, prophylactic treatment, and
triptans (P\ 0.001).
Conclusions Patients with primary headaches, mainly
young adults, are exposed to high polypharmacy, compa-
rable to that of the elderly. Because increased numbers of
drugs increase the risk of adverse reactions, the many
medications concomitantly taken by primary headache
sufferers should be frequently reviewed.
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Key Points
Among young adult patients with primary
headaches, especially chronic headaches,
polypharmacy is common and comparable to that
found among the elderly.
Most polypharmacy is due to prescription drugs that
patients take to treat their headaches and only to a
lesser extent to those used to treat other
comorbidities.
These results suggest that medications should be
reviewed regularly in primary headache patients, and
to avoid risks, discontinuing ineffective or harmful
medications may be necessary.
1 Introduction
Polypharmacy is defined as the use of multiple medications
by an individual patient [1]. This can be appropriate, or
even necessary, when no alternatives exist for treating
several comorbidities for which different drugs are
required and helpful [2]. Nevertheless, concern is growing
regarding the risks and complications of polypharmacy [3].
Increases in the number of concomitant medications
increases the risk of adverse reactions, which can increase
than that of individual drugs. Polypharmacy can also
decrease treatment adherence [3, 4] and cause suboptimal
health outcomes, wasted medications and a lower quality of
life [1, 5, 6]. Polypharmacy has been extensively studied
and reported to be prevalent and increasing among the
elderly, because of the many subjects with multimorbidities
that require multiple medications [4, 7–9].
The prevalence of and complications related to
polypharmacy have been evaluated in patients with cancer
pain and chronic non-malignant pain [5, 10]; however, few
data [11, 12] exist on this issue for primary headaches,
despite these disorders being exposed to the possibility of
polypharmacy.
Primary headaches are widespread in the general pop-
ulation and prevalent in females [13]. They occur in three
main forms: migraine, whose 1-year prevalence is 15% in
the general population; tension-type headache, the most
prevalent headache, affecting 60% of the adult population;
and cluster headache, the least frequent type, occurring in
less than 1% of the population [13]. They often remain
episodic and improve over time, but may worsen and
become chronic and disabling and negatively impact the
sufferers’ quality of life [14]. Moreover, they are often
associated with other medical and psychiatric conditions
[15] that require additional pharmacological treatments.
The pathophysiology of primary headaches remains
incompletely understood, and no causal and definitive
therapies are actually available for these disorders, despite
the recent progress in this field [13, 16]. Headache man-
agement is mainly based on pharmacological treatments
comprising drugs for acute treatment, such as nonsteroidal
anti-inflammatory drugs (NSAIDs), triptans, analgesics,
muscle relaxants and anti-nausea drugs, and preventive
drugs, such as antidepressants, antiepileptics, beta-blocking
agents, calcium channel blockers, serotonin antagonists
[16] and onabotulinumtoxinA [17]. Acute treatment is
always prescribed to headache patients, whereas preventive
treatment is recommended in the case of frequent, severe
and long-lasting attacks, when symptomatic medications
induce only limited effects or are contraindicated, or if the
patient’s quality of life is seriously affected. Preventive
treatment is directed to specifically decrease the frequency
of headache attacks and should be taken usually from 3 to
6 months. During the treatment, the patients must often
continue taking acute medications for the attack and may
need other medications for associated or new-onset ill-
nesses [16].
The objectives of the present study were as follows: (1)
to evaluate the prevalence, characteristics and risk factors
of polypharmacy, drug utilization and comorbidities in
patients with primary headaches afferent to a headache
centre; (2) to analyse whether these variables differ
between episodic and chronic headache sufferers.
2 Methods
2.1 Study Design and Study Sample
This cross-sectional, observational study evaluated all
drugs regularly taken by 300 primary headache patients
consecutively afferent to a headache centre. Patients under
18 years old and suffering from secondary headaches were
excluded. The study was approved by the Ethical Com-
mittee of the Province of Modena (Prot. n. 3610/C.E., file
126/13). All patients provided written consent to partici-
pate in the study and were enrolled from October 1st, 2013
to December 23rd, 2014. The present study is based on
unpublished data collected during a research project
focused on quantitative determination of triptans and
headache prophylactic drugs in hair samples [18–21].
The patients (Table 1) were divided into two groups,
namely, (1) episodic headaches (headaches occurring
for\ 15 days/month for[ 3 months) and (2) chronic
headaches (headaches occurring for C 15 days/month
for[ 3 months), based on the diagnostic criteria of the
International Classification of Headache Disorders (ICHD)
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(3rd edition, beta version) [22]. Group 1 diagnoses were
migraine without aura (70%, n = 126), migraine with aura
(3%, n = 6), migraine with and without aura (5%, n = 9),
and infrequent episodic (18%, n = 33) and frequent epi-
sodic (4%, n = 7) tension-type headaches. Group 2 diag-
noses were chronic migraine (87%, n = 103) and chronic
tension-type headaches (13%, n = 16). All patients suf-
fering from chronic migraine overused symptomatic med-
ications. Most patients were at least high school graduates,
employed, Caucasian, married, and outpatients; female
patients represented 95% of all study subjects. The average
age for the entire cohort was 42.81± 13.21 years. Patients
with chronic headaches were significantly older
(47.79± 11.32) than those with episodic headaches
(39.54± 13.08) (P\ 0.0001, Student’s t test). Over 92%
of the total sample were aged 18–60 years (nearly 70% of
the patients were aged 18–50 years). Episodic headaches
were significantly more frequent in patients aged
18–29 years (P\ 0.001, Chi square test), while chronic
headaches significantly prevailed in patients aged
51–60 years (P\ 0.001, Chi square test) (see the Elec-
tronic Supplementary Material, online resource, ESM_1).
2.2 Study Variables
We used a form to collect demographic data from each
patient, which included headache diagnosis, comorbidi-
ties and a detailed pharmacological history including all
medications (dose and route of administration) taken
regularly over the previous 3 months. The collected data
were assessed based on headache diaries and were dis-
cussed between the doctor and patient before being
recorded.
2.3 Data Analysis and Statistics
The total case studies were descriptively analysed, and
groups 1 and 2 were compared in terms of the following
variables: demographic data, number and type of medical
and psychiatric comorbidities, presence of polypharmacy
(simultaneous use of five or more medications), excessive
Table 1 Demographic data and comparison between chronic and episodic headache
Variable Total n (%) Episodic headache n (%) Chronic headache n (%) OR [95% CI]a P valueb
No. of patients 300/300 (100.0) 181/300 (60.3) 119/300 (39.7) – –
Inpatients 73/300 (24.3) 19/181 (10.5) 54/119 (45.4) 7.08 [3.69–13.59] \ 0.0001
Outpatients
First visit 140/300 (46.7) 102/181 (56.4) 38/119 (31.9) 0.36 [0.22–0.60] \ 0.0001
Control visit 87/300 (29.0) 60/181 (33.1) 27/119 (22.7) 0.59 [0.35–1.01] 0.0512
Mean age ± SD (years) 42.81 ± 13.21 39.54 ± 13.08 47.79 ± 11.32 – \ 0.0001
Range (years) 18–76 18–76 18–76 – –
Females 286/300 (95.3) 172/181 (95.0) 114/119 (95.8) 1.19 [0.39–3.66] 0.7573
Education
Primary school 17/300 (5.7) 11/181 (6.1) 6/119 (5.0) 0.82 [0.29–2.29] 0.7048
Secondary school 85/300 (28.3) 51/181 (28.2) 34/119 (28.6) 1.02 [0.61–1.70] 0.9409
High school 124/300 (41.3) 75/181 (41.4) 49/119 (41.2) 0.99 [0.62–1.58] 0.9644
University degree 74/300 (24.7) 44/181 (24.3) 30/119 (25.2) 1.05 [0.61–1.79] 0.8597
Occupation
Employed 207/300 (69.0) 119/181 (65.7) 88/119 (73.9) 1.48 [0.88–2.47] 0.1335
Ethnicity
Caucasian 289/300 (96.3) 171/181 (94.5) 118/119 (99.2) 6.90 [0.86–55.68] 0.0890
African 8/300 (2.7) 7/181 (3.9) 1/119 (0.8) 0.21 [0.03–1.76] 0.1120
Asian 3/300 (1.0) 3/181 (1.7) 0/119 (0.0) 0.00 0.1590
Marital status
Married 167/300 (55.7) 88/181 (48.6) 79/119 (66.4) 2.09 [1.28–3.40] 0.0025
Values are n (%) unless otherwise stated
CI confidence interval, OR odds ratio, SD standard deviation
achronic vs episodic headache OR
bp value is derived from a Student’s t test with equal variances for mean age comparison and from a Chi square test for homogeneity of odds for
the others
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medications (simultaneous use of ten or more medications),
number, type and pharmacological class of the drugs taken
to treat headaches (acute and prophylaxis), and other dis-
eases over the previous 3 months. Moreover, we evaluated
the dosage forms taken by the patients for acute treatment
and the number of patients using over-the-counter (OTC)
and prescription drugs. Medications were coded per the
Anatomical Therapeutic Chemical (ATC) classification
system. Finally, we performed a multivariate logistic
regression analysis to assess the polypharmacy risk factors.
Statistical analysis was conducted using Stata IC13
software. Continuous variables were expressed as the
mean ± standard deviation, and binary variables were
expressed as subject count, percentages and odds ratios
(ORs). Mean comparison tests were performed using Stu-
dent’s t test for independent data. Binary variables were
compared using the Chi square test for homogeneity of
odds. To avoid confounding in the multivariate logistic
regression analysis, the binary variable indicating the
presence or absence of polypharmacy was chosen as the
dependent variable, whilst the independent variables were
those significantly associated with chronic headaches.
Model accuracy was assessed by the receiver-operator
characteristic (ROC) curve (see online resource,
ESM_2.pdf). P values less than 0.05 were considered
significant.
3 Results
Headache patients (Table 2) were simultaneously taking an
average of more than 4 medications for 3 months, of which
at least three were to manage their headaches. Chronic
sufferers took significantly more medications than episodic
patients (P\ 0.0005, Student’s t test). The prevalence of
polypharmacy (five or more medications) among the total
cohort was 40.7%. In patients with chronic headache, the
polypharmacy prevalence was doubled compared with that
in the episodic headache patients (P\ 0.0001, Chi square
test); excessive polypharmacy (ten or more medications)
affected only a minority of the total sample. Most subjects
and all chronic patients took acute headache medications.
Nearly 65% of patients with chronic headaches took at
least one prophylactic medication, almost twice as many as
episodic sufferers (P\ 0.0001, Chi square test). More than
three-quarters of the patients were also taking other drugs
that were not for headaches.
The most common acute treatment medications
(Table 3) were NSAIDs, followed by triptans, and anal-
gesic combinations. Few patients were taking opioids,
muscle relaxants or antiemetics. The most frequent active
principles were ketoprofen (41%) among NSAIDs,
eletriptan (31%) among triptans, and tramadol (86%)
among opioids. Patients with chronic headache took trip-
tans (P\ 0.0001), analgesic combinations (P\ 0.05) and
Table 2 Characteristics of polypharmacy in the total sample and comparison between chronic and episodic headache patients (some patients
took more than one medication at the same time)
Variable Total (n = 300),
n (%)
Episodic headache
(n = 181), n (%)
Chronic headache
(n = 119), n (%)
OR [95% CI]a P valueb
No. of medications taken per patient
Mean ± SD 4.37 ± 2.46 3.64 ± 2.05 5.49 ± 2.63 0.0001
Range 1–13 1–10 1–13
No. of headache medications per patient
Mean ± SD 3.79 ± 1.96 2.22 ± 1.30 3.55 ± 1.90 \ 0.0001
Range 0–9 0–7 1–9
No. of patients taking 5 or more and 10 or more drugs per day
C 5 medications 122/300 (40.7) 52/181 (28.7) 70/119 (58.8) 3.54 [2.13–5.91] \ 0.0001
C 10 medications 9/300 (3.0) 3/181 (1.7) 6/119 (5.0) 3.15 [0.77–12.97] 0.0933
Type of taken medications/supplements
Acute headache medications 291/300 (97.0) 172/181 (95.0) 119/119 (100.0) ? 0.0137
Prophylaxis headache medications 132/300 (44.0) 55/181 (30.4) 77/119 (64.7) 4.20 [2.49–7.09] \ 0.0001
Other medications 230/300 (76.7) 133/181 (73.5) 97/119 (81.5) 1.59 [0.90–2.82] 0.1082
Dietary supplements 62/300 (20.7) 38/181 (21.0) 24/119 (20.2) 0.95 [0.54–1.69] 0.8629
Values are n (%) unless otherwise stated
CI confidence interval, OR odds ratio, SD standard deviation
achronic vs episodic headache OR
bp value is derived from a Student’s t test with equal variances for the comparison of the number of medications taken daily and from a Chi
square test for homogeneity of odds for all the other comparison
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opioids (P\ 0.005) (Chi square tests) significantly more
than patients with episodic headache. A minority of the
sample (n = 75/300, 25%) used only OTCs, with no sta-
tistically significant differences between patients with
chronic headaches (n = 28/119, 23.5%) and those with
episodic headaches (n = 47/181, 25.97%). Most patients
(Table 4) took acute treatments orally, and subcutaneous
administration was used more by chronic headache suf-
ferers than by episodic headache sufferers (P\ 0.05, Chi
square test).
The most commonly used prophylactic drugs (Table 5)
were antidepressants and antiepileptics. The most pre-
scribed active principles were amitriptyline (51%) among
antidepressants and topiramate (57%) among antiepilep-
tics. The percentage of chronic patients treated with
antiepileptic drugs was double that of episodic headache
patients (P\ 0.05, Chi square test). A majority of patients
(Table 6), and more patients with episodic headaches than
with chronic headaches (P\ 0.05, Chi square test), used
only one medication for acute treatment. Patients with
Table 3 Therapeutic classes of medications taken by the 291 patients for acute treatment and comparison between chronic and episodic
headache patients (some patients took more than one symptomatic drug)
Therapeutic class Total (n = 291),
n (%)
Episodic headache
(n = 172), n (%)
Chronic headache
(n = 119), n (%)
OR [95% CI]a P valueb
NSAIDs 214/291 (73.5) 133/172 (77.3) 81/119 (68.1) 0.63 [0.37–1.06] 0.0789
Triptans 143/291 (49.1) 65/172 (37.8) 78/119 (65.5) 3.13 [1.55–5.20] \0.0001
Analgesic combinations 63/291 (21.6) 29/172 (16.9) 34/119 (28.6) 1.97 [1.12–3.49] 0.0173
Opioids 13/291 (4.5) 2/172 (1.2) 11/119 (9.2) 8.66 [1.82–41.09] 0.0011
Muscle relaxants 9/291 (3.1) 3/172 (1.7) 6/119 (5.0) 2.99 [0.73–12.31] 0.1107
Antiemetics 5/291 (1.7) 1/172 (0.6) 4/119 (3.4) 5.95 [0.65–54.77] 0.0733
CI confidence interval, OR odds ratio, NSAID nonsteroidal anti-inflammatory drug
achronic vs episodic headache OR
bp value is derived from a Chi square test for homogeneity of odds
Table 4 Dosage forms of medications taken by the 291 patients for acute treatment and comparison between chronic and episodic headache
patients (some patients took more than one symptomatic drug of more than one dosage form)
Dosage form Total (n = 291),
n (%)
Episodic headache
(n = 172), n (%)
Chronic headache
(n = 119), n (%)
OR [95% CI]a P valueb
Oral 274/291 (94.2) 161/172 (93.6) 113/119 (95.0) 1.29 [0.46–3.59] 0.6290
Intramuscolar 59/291 (20.3) 31/172 (18.0) 28/119 (23.5) 1.40 [0.79–2.49] 0.2515
Subcutaneous 31/291 (10.7) 13/172 (7.6) 18/119 (15.1) 2.18 [1.02–4.67] 0.0400
Rectal 26/291 (8.9) 12/172 (7.0) 14/119 (11.8) 1.78 [0.79–4.01] 0.1599
Nasal spray 6/291 (2.1) 3/172 (1.7) 3/119 (2.5) 1.46 [0.29–7.37] 0.6472
CI confidence interval, OR odds ratio
achronic vs episodic headache OR
bp value is derived from a Chi square test for homogeneity of odds
Table 5 Classes of medications taken by the 132 patients for prophylactic treatment and comparison between chronic and episodic headache
patients (some patients took more than one preventive drug)
Therapeutic class Total (n = 132),
n (%)
Episodic headache
(n = 55), n (%)
Chronic headache
(n = 77), n (%)
OR [95% CI]a P valueb
Antidepressants 102/132 (77.3) 41/55 (74.6) 61/77 (79.2) 1.30 [0.57–2.97] 0.5290
Antiepileptics 29/132 (22.0) 7/55 (12.7) 22/77 (28.6) 2.74 [1.06–7.13] 0.0308
Beta-blocking agents 12/132 (9.1) 5/55 (9.1) 7/77 (9.1) 1.00 [0.30–3.35] 1.0000
Calcium channel blockers 9/132 (6.8) 5/55 (9.1) 4/77 (5.2) 0.55 [0.14–2.16] 0.3831
CI confidence interval, OR odds ratio
achronic vs episodic headache OR
bp value is derived from a Chi square test for homogeneity of odds
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chronic headache used four medications for acute treatment
(P\ 0.05, Chi square test) and two medications for pro-
phylaxis (P\ 0.0001, Chi square test), significantly more
than those with episodic headaches.
The first three classes of other medications (Table 7)
taken were, in order of frequency, drugs for acid-related
disorders (the most used were proton-pump inhibitors,
82%), psycholeptics (the most used were benzodiazepines,
Table 6 Number of different active principles for headache treatment taken concurrently in the total sample and comparison between chronic
and episodic headache patients (some patients took both acute and prophylactic medications)
No. of medications taken
for headache treatment
Total (n = 300),
n (%)
Episodic headache
(n = 181), n (%)
Chronic headache
(n = 119), n (%)
OR [95% CI]a P valueb
For acute treatment
1 109/300 (36.3) 76/181 (42.0) 33/119 (27.7) 0.53 [0.32–0.88] 0.0122
2 78/300 (26.0) 47/181 (26.0) 31/119 (26.0) 1.00 [0.59–1.70] 0.9871
3 59/300 (19.7) 33/181 (18.2) 26/119 (21.8) 1.25 [0.70–2.23] 0.4415
4 27/300 (9.0) 11/181 (6.1) 16/119 (13.4) 2.40 [1.06–5.42] 0.0294
5 13/300 (4.3) 5/181 (2.8) 8/119 (6.7) 2.54 [0.80–8.01] 0.0999
6 1/300 (0.3) 0/181 (0) 1/119 (0.8) ? 0.2175
7 4/300 (1.3) 0/181 (0) 4/119 (3.4) ? 0.0132
For prophylactic treatment
1 95/300 (31.7) 48/181(26.5) 47/119 (39.5) 1.81 [1.10–2.98] 0.0183
2 29/300 (9.7) 5/181(2.8) 24/119 (20.2) 8.89 [3.14–25.19] \0.0001
3 8/300 (2.7) 2/181 (1.1) 6/119 (5.0) 4.75 [1.03–24.30] 0.0587
CI confidence interval, OR odds ratio
achronic vs episodic headache OR
bp value is derived from a Chi square test for homogeneity of odds
Table 7 Other medications [the Anatomical Therapeutic Chemical (ATC) classification, 2nd level, therapeutic subgroup] taken by the 230
patients and comparison between chronic and episodic headache patients (some patients took more than one symptomatic drug)
Other medications (ATC classification) Total (n = 230),
n (%)
Episodic headache
(n = 133), n (%)
Chronic headache
(n = 97), n (%)
OR [95% CI]a P valueb
Drugs for acid related disorders 50/230 (21.7) 17/133 (12.8) 33/97 (34.0) 3.52 [1.78–6.97] 0.0001
Psycholeptics 46/230 (20.0) 17/133 (12.8) 29/97 (29.9) 2.91 [1.46–5.78] 0.0014
Thyroid therapy 43/230 (18.7) 26/133 (19.5) 17/97 (17.5) 0.87 [0.44–1.72] 0.6982
Anti-inflammatory and antirheumatic products 42/230 (18.3) 23/133 (17.3) 19/97 (19.6) 1.16 [0.59–2.29] 0.6572
Antihypertensives 39/230 (17.0) 17/133 (12.8) 22/97 (22.7) 2.00 [1.02–4.05] 0.0487
Sex hormones and modulators of the genital system 37/230 (16.1) 25/133 (18.8) 12/97 (12.4) 0.61 [0.29–1.29] 0.1912
Psychoanaleptics 26/230 (11.3) 13/133 (9.8) 13/97 (13.4) 1.43 [0.63–3.25] 0.3919
Antibacterial for systemic use 20/230 (8.7) 13/133 (9.8) 7/97 (7.2) 0.72 [0.27–1.88] 0.4957
Lipid modifying agents 14/230 (6.1) 5/133 (3.8) 9/97 (9.3) 2.62 [0.84–8.16] 0.0845
Antihistamines for systemic use 13/230 (5.7) 10/133 (7.5) 3/97 (3.1) 0.39 [0.1–1.48] 0.1521
Drugs for functional gastrointestinal disorders 12/230 (5.2) 6/133 (4.5) 6/97 (6.2) 1.40 [0.43–4.48] 0.5737
Corticosteroids for systemic use 11/230 (4.8) 5/133 (3.8) 6/97 (6.2) 1.69 [0.50–5.73] 0.3955
Analgesics 9/230 (3.9) 5/133 (3.8) 4/97 (4.1) 1.10 [0.29–4.22] 0.8883
Drugs for obstructive airway diseases 7/230 (3.0) 6/133 (4.5) 1/97 (1.0) 0.22 [0.03–1.89] 0.1300
Muscle relaxants 6/230 (2.6) 3/133 (2.3) 3/97 (3.1) 1.38 [0.27–7.03] 0.6947
Antiepileptics 3/230 (1.3) 1/133 (0.8) 2/97 (2.1) 2.78 [0.13–16.09] 0.8754
Drugs for treatment of bone diseases 3/230 (1.3) 1/133 (0.8) 2/97 (2.1) 2.78 [0.13–16.09] 0.8754
Immunosuppressants 1/230 (0.4) 0/133 (0.0) 1/97 (1.0) ? 0.2416
CI confidence interval, OR odds ratio
achronic vs episodic headache OR
bp value is derived from a Chi square test for homogeneity of odds
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92%) and thyroid therapy drugs (the most used was
levothyroxine, 91%). Chronic headache patients took drugs
for acid-related disorders (P\ 0.0005), psycholeptics
(P\ 0.005), and antihypertensives (P\ 0.05) (Chi square
test) more than episodic headache patients. Overall, 64% of
the 300 patients (n = 192) were being treated with central
nervous system (CNS) drugs, with chronic patients being
significantly more prevalent (n = 96/119, 80.67%) than
episodic patients (n = 96/181, 53.04%) (P\ 0.0001,
OR = 3.70 [2.10-6.50], Chi square test).
Nearly 60% of the sample (Table 8) suffered from at
least one comorbidity in addition to headaches. Patients
with chronic headaches had significantly more comorbidi-
ties than those with episodic headaches, with at least one
(P\ 0.05) and two comorbidities (P\ 0.005, Chi square
test). The first three most frequent comorbidities (Table 9)
were gastrointestinal (gastritis being the most common,
64%), endocrinological (thyroiditis being the most com-
mon, 78%) and rheumatological disorders (fibromyalgia
being the most common, 61%). Patients with chronic
headache suffered from gastrointestinal and rheumatolog-
ical disorders more often than those with episodic head-
aches (P\ 0.005, Chi square test), while patients with
episodic headaches suffered from respiratory disorders
(P\ 0.005, Chi square test) significantly more than those
with chronic headaches. The variables significantly asso-
ciated with polypharmacy (Table 10) were prophylactic
treatment, triptans (P\ 0.001) or other analgesic combi-
nation (P\ 0.005) for acute treatment, and at least one
comorbidity (P\ 0.001, Chi square test).
4 Discussion
Our results indicate that polypharmacy is a significant issue
among primary headache patients. On average, these
patients (Table 2) took 4.37 medications together for at
least three months, and 40.7% of the sample simultane-
ously used five or more medications (polypharmacy).
These values were (1) higher than those detected among
Table 8 Medical and/or psychiatric comorbidities in the 300 primary headache patients and comparison between chronic and episodic headache
patients
Number of comorbidities Total (n = 300), n (%) Episodic headache
(n = 181), n (%)
Chronic headache
(n = 119), n (%)
OR [95% CI]a P valueb
At least 1 179/300 (59.7) 98/181 (54.1) 81/119 (68.1) 1.81 [1.11–2.94] 0.0164
1 107/300 (35.7) 68/181 (37.6) 39/119 (32.8) 0.81 [0.50–1.32] 0.3970
2 52/300 (17.3) 22/181 (12.2) 30/119 (25.2) 2.44 [1.31–4.52] 0.0035
[2 20/300 (6.7) 8/181 (4.4) 12/119 (10.1) 2.43 [0.95–6.17] 0.0548
CI confidence interval, OR odds ratio
achronic vs episodic headache OR
bp value is derived from a Chi square test for homogeneity of odds
Table 9 Distribution by type of disorder in the 179 patients with at least one comorbidity and comparison between chronic and episodic
headache patients (some patients suffered from more than one comorbidity at the same time)
Comorbidity type Total (n = 179),
n (%)
Episodic headache
(n = 98), n (%)
Chronic headache
(n = 81), n (%)
OR [95% CI]a P valueb
Gastrointestinal 55/179 (30.7) 21/98 (21.4) 34/81 (42.0) 2.65 [1.35–5.20] 0.0031
Endocrinological 51/179 (28.5) 31/98 (31.6) 20/81 (24.7) 0.71 [0.36–1.38] 0.3072
Rheumatological 51/179 (28.5) 19/98 (19.4) 32/81 (39.5) 2.72 [1.36–5.41] 0.0031
Psychiatric 40/179 (22.3) 18/98 (18.4) 22/81 (27.2) 1.66 [0.81–3.38] 0.1610
Cardiological 32/179 (17.9) 14/98 (14.3) 18/81 (22.2) 1.71 [0.79–3.73] 0.1690
Respiratory 17/179 (9.5) 15/98 (15.3) 2/81 (2.5) 0.14 [0.03–0.66] 0.0036
Urological 12/179 (6.7) 7/98 (7.1) 5/81 (6.2) 0.86 [0.26–2.81] 0.7967
Haematological 11/179 (6.1) 7/98 (7.1) 4/81 (4.9) 0.68 [0.19–2.41] 0.5421
Obstetric-gynaecological 6/179 (3.4) 5/98 (5.1) 1/81 (1.2) 0.23 [0.03–2.07] 0.1536
Neurological 1/179 (0.6) 0/98 (0.0) 1/81 (1.2) ? 0.2714
CI confidence interval, OR odds ratio
achronic vs episodic headache OR
bp value is derived from a Chi square test for homogeneity of odds
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fibromyalgia patients, where polypharmacy was defined as
simultaneous intake of three or more medications, which
affected 40% of patients [23]; (2) lower than those of
European pain and cancer patients who took an average of
7.8 medications, with over 25% using ten or more medi-
cations [24]; and (3) comparable to those found in the
elderly, as approximately 30–40% of those aged over
65 years are treated with five or more medications [8], and
those aged over 80 years have a polypharmacy prevalence
of 57.7% [6]. Notably, our sample was primarily young
adult women who were married and working. Here,
polypharmacy was mainly due to the medications that
patients took to treat their headaches, possibly to perform
their daily activities despite the headache. Chronic head-
ache patients took even more medications. Polypharmacy
doubled from 28.7% for patients with episodic headache to
58.8% for patients with chronic headache (P\ 0.0001).
Overall, these drugs were appropriate as per the guidelines
for treating primary headaches [16]. The most used drug
classes for acute treatment (Table 3) were NSAIDs
(73.5%), followed by triptans (49.1%). The oral route of
administration (Table 4) was preferred by 94.2% of the
sample. Subcutaneous formulations, which allow rapid
drug absorption even with nausea and/or vomiting [25],
were used more by patients with chronic headaches
(15.1%) than by those with episodic headaches (7.6%)
(P\ 0.05). The guidelines emphasize the importance of
prophylactic treatment to reduce headache frequency [16];
however, current prophylactic drugs have limited efficacy.
In clinical trials, they decreased the frequency of attacks by
50% or more in only 55–66% of patients [26]. In clinical
practice, their efficacy was even lower. Of patients with
chronic headache, 64.7% had been taking prophylactic
drugs for 3 months, but continued to suffer from chronic
headaches. The most common prophylactic drugs were
among those at the first level of recommendation per the
guidelines [16], which were (Table 5) antidepressants
(77.3%, the most used was amitriptyline 51%) and
antiepileptics (22%, the most used was topiramate, 57%).
The treatment of pain often requires combinations of
various drugs that act with different mechanisms to achieve
a synergistic effect [10]. In addition, patients with disabling
headaches often consult many specialists looking for a
cause and a cure by frequently receiving combinations of
prescription medications [12]. This approach generates
increased exposure to potential harm [10]. In our study
(Table 6), many patients simultaneously used several
medications together, both for acute treatment (60.6% used
at least two) and for prophylaxis (12.4% used at least two).
In the general population, patients with headache often
self-treat their condition with OTC analgesics [27–29].
Instead, in our sample of patients who were referred to a
headache centre, self-medication with prescription drugs
was more common than with OTCs, which involved only
25% of the sample.
Some of our patients’ polypharmacy treated disorders
other than headaches. Medical and psychiatric comorbidi-
ties are common among pain patients and represent pre-
disposing factors to polypharmacy [30, 31]. In our study
(Table 7), the majority of patients (n = 230/300, 76.7%)
were taking other medications, and 59.7% (n = 179/300)
suffered (Table 8) from at least one comorbidity. The four
most used classes of other medications (Table 7) were
drugs for acid-related disorders, psycholeptics, thyroid
therapy drugs and anti-inflammatory and antirheumatic
agents. Consistent with these classes, the most frequent
comorbidities (Table 9) were gastrointestinal disorders,
followed by endocrinological, rheumatological and psy-
chiatric disorders. Endocrinological disorders were almost
exclusively thyroid diseases. The Italian region where the
study was conducted (Emilia-Romagna) is characterized by
an important iodine deficiency that affects its inhabitants’
thyroid health, regardless of headaches [32]. Insomnia is
very common among patients with primary headaches [33],
Table 10 Multivariate logistic
regression analysis for risk
factors of polypharmacy among
the 300 primary headache
patients
Variable ORa P valueb
Mean age of the patients - 0.026 to 0.023 0.911
Inpatients - 0.649 to 0.798 0.839
Married/cohabiting - 1.027 to 0.174 0.164
Chronic headache - 0.128 to 1.141 0.118
Prophylaxis treatment 0.684 to 1.953 \ 0.001
Triptans for acute treatment 0.563 to 1.783 \ 0.001
Analgesic combination for acute treatment 0.553 to 2.014 0.001
Opioid for acute treatment - 0.035 to 3.685 0.055
At least one comorbidity 1.106 to 2.400 \ 0.001
CI confidence interval, OR odds ratio
aOR of polypharmacy
bp value is derived from a Chi square test for homogeneity of odds
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especially those with migraines [34]. Furthermore,
depression is the most frequent comorbidity with chronic
pain [31]. Likely due to these disorders, 20% and 11.3% of
patients consumed psycholeptics and psychoanaleptics,
respectively. However, the overall use of CNS medications
reached 64%, significantly higher than the 35% seen in the
elderly [35]. Polypharmacy was higher in subjects with
chronic headaches. Moreover, 68.1% had comorbidities
and took drugs for acid-related disorders (P\ 0.0001),
psycholeptics (P\ 0.005) and antihypertensives
(P\ 0.05) significantly more than those with episodic
headaches.
Another part of our patients’ polypharmacy appeared to
depend on a prescribing cascade; i.e. from other medica-
tions prescribed to treat adverse drug reactions caused by
the drugs used to treat the headaches and comorbidities.
For example, the high use of NSAIDs leads to gastropathy
as its most common side effect [36]; thus, it is unsurprising
that the most employed concomitant medications were for
treating acid-related disorders. In addition, the medications
used to treat comorbidities may in turn have caused
headache as a side effect, thereby increasing the patient’s
suffering. In fact, headache is one of the most frequent
reactions induced by numerous drugs belonging to a large
variety of therapeutic classes, and it occurs at therapeutic
dose levels. Drugs for the cardiovascular system and in
particular antihypertensive agents such as angiotensin-
converting-enzyme (ACE) inhibitors, sartans and calcium
channel blockers are among those that most frequently
cause headache as an adverse reaction [37]. Seventeen per
cent of our sample (Table 7) were taking antihypertensive
drugs of this type. With the NSAIDs, CNS complaints are
less common than gastrointestinal side effects. However,
headache, dizziness and drowsiness have been reported
during clinical trials with almost all NSAIDs [37]. These
drugs were used for disorders other than headache for
18.3% of the sample. Proton-pump inhibitors have also
been associated with headache as a common adverse effect
[38]. In our sample, proton-pump inhibitors were the most
used class of drugs for acid-related disorders, taken by
21.7% of patients. Finally, headache is a common side
effect of various classes of CNS drugs, some taken by our
patients, such as sedative-hypnotic agents (particularly
benzodiazepines) and antidepressants (primarily specific
inhibitors of serotonin re-uptake such as fluoxetine,
paroxetine and sertraline) [38]. In general, headache as an
adverse reaction has no specific features and can simulate a
primary headache; it can be very difficult to be recognized
and diagnosed in a patient who already suffers from
headaches. However, it may have the potential to aggravate
the primary headache [38].
The most common causes of polypharmacy in the
studied patients appeared as a result of the drugs taken for
headache management, followed by drugs used for treating
comorbidities, and finally, drugs taken for the treatment of
side effects from previous medication. We cannot exclude
the fact that some agents which cause headache as a side
effect may modify or worsen concomitant conditions such
as insomnia, anxiety and depression, making them resistant
to treatments and ultimately prompting further intake of
appropriate medication in an attempt to manage these
additional effects. Instead of resolving the headache, this
cycle of drug intake may lead to chronicization and overuse
of medications, potentially causing further complications.
Lastly, when two or more drugs are co-administered,
there is always the possibility of drug–drug interactions,
either kinetic or dynamic. The most common mechanisms
of kinetic interactions are represented by the induction or
inhibition of enzymes of the cytochrome P450 (CYP)
system. This system plays an important role in the dispo-
sition of a large number of drugs, including those used for
primary headache treatment [39, 40]. The risk of having
clinically significant pharmacokinetic drug–drug interac-
tions seems to be limited in patients with low frequency
headaches, but could be higher in chronic headache suf-
ferers [41]. Furthermore, if the interaction involves a drug
with a narrow therapeutic window, the consequence may
be clinically significant. On the basis of the pharmaco-
logical classes most commonly used by our patients, and
keeping in mind the high frequency of concomitant
rheumatological disorders that concerned 28.5% of
patients, it seems important to recommend avoidance of
NSAIDs plus drugs with a narrow therapeutic range (i.e.
methotrexate), and to also pay attention to the simultaneous
use of substrates and inhibitors of CYP2D6 (i.e. metoclo-
pramide, beta-blocking agents, antidepressants) and of
CYP3A4 (i.e. eletriptan, verapamil) [39].
The employment of multiple treatments, often decided
on an empirical basis, could be avoided if the precision
medicine approach [42] was implemented in the manage-
ment of primary headache. Unfortunately, there have been
no specific genetic or epigenetic abnormalities associated
with a particular type of headache to assist with deter-
mining optimal treatment [43]. In clinical practice, acute
and preventive headache treatments are prescribed on the
basis of diagnosis, taking into account the comorbidity of
the patient and the safety profile of the drug [16], but
without the possibility of efficient and optimal individual-
ized treatment for the patient. Recently, calcitonin gene-
related peptide (CGRP) has emerged as a key neuropeptide
involved in the pathophysiology of migraine, and clinical
trials are ongoing on various monoclonal antibodies tar-
geted against CGRP or its receptors, which appear to yield
promising results [44]. Perhaps, in the future, these anti-
bodies will allow the management of migraine without
polypharmacy, and eliminate the risk of chronic migraine
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progression and the overuse of symptomatic medications
[43].
Our study has some limitations that should be noted. It
was a cross-sectional study, and the data were derived from
a secondary analysis. Polypharmacy is more frequent in
females [6], and primary headaches (except for cluster
headaches, which were unaccounted for in our sample)
prevail among women [45]. Therefore, the female preva-
lence in our study should have allowed greater insight into
polypharmacy in primary headache patients. The results
refer to patients afferent to a headache centre and were
limited by the definitions used. We adopted the numerical
definition of polypharmacy identified as the cut-off that
signals the clinician to review the patient’s current medi-
cations [46, 47]. Moreover, this is the first study that
quantified and analysed polypharmacy in primary headache
patients.
Polypharmacy may be appropriate and necessary in
treating pain patients [10]; however, considering that pri-
mary headaches are not life-threatening and recur over
time, the intake of so many medications, several of which
are psychoactive, should be reviewed frequently in young
adult subjects. If the risk-to-benefit ratio is unfavourable,
the proper intervention should be to stop medications with
poor efficacy that reduce the patients’ quality of life (i.e.
deprescribing), even if theoretically appropriate [48]. This
process is uniquely relevant to headaches for the following
reasons: (1) Headaches are the most common adverse
reaction to many drugs [38]; therefore, the more medica-
tions a patient takes, the more likely it is that part of their
headache is due to the drugs. (2) Analgesic overuse with-
drawal is considered fundamental in treating chronic
headaches; this intervention alone could reduce headache
frequency [49]. (3) Some headaches are recognized as
‘‘refractory’’ [50]; in these cases, continuing prophylaxis
treatments, often in unprecedented combinations that are
ineffective after a proper trial and that cause disturbing side
effects even if not serious, would be irrational polyphar-
macy [51].
5 Conclusion
In summary, our results show that the prevalence of
polypharmacy in patients suffering from primary head-
aches is high and comparable to that of the elderly [1, 52].
A twenty-year-old migraine patient, during a control visit
to review the medications she was taking, exclaimed, ‘‘I
take more medications than my grandfather!’’ However, in
patients with primary headaches, polypharmacy seems an
inevitable consequence of attempting to manage the
headaches; in fact, risk factors associated with this condi-
tion (Table 10) were prophylactic treatment, use of triptans
and analgesic combinations and comorbidities, but not
patient age.
We hope that our work can help clinicians to recognize
headache sufferers’ probable polypharmacy before pre-
scribing other medications; this may represent a step
towards improving current primary headache management.
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